Clinical and economic impact of clinical pharmacy service on hyperlipidemic management in Hong Kong

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 16, Issue 1, 2011, Pages 43-52

  Chung, Jennifer S T ^a   Lee, Kenneth K C ^a   Tomlinson, Brian ^b   Lee, Vivian W Y ^a  

^a Chinese University of Hong Kong   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

clinical pharmacy service; coronary heart disease; dyslipidemia

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; COLESTYRAMINE; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL PHARMACY; CONTROLLED STUDY; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH EDUCATION; HONG KONG; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OUTCOME ASSESSMENT; PHARMACIST; PRIORITY JOURNAL; PROSPECTIVE STUDY; TELEPHONE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HEALTH CARE COSTS; HEALTH PROMOTION; HONG KONG; HOSPITALS, TEACHING; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIFE STYLE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PATIENT EDUCATION AS TOPIC; PHARMACEUTICAL SERVICES; RISK FACTORS; TRIGLYCERIDES;

EID: 79951498282     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410380207     Document Type: Article

References (37)

1. Murray CJ, Lopez AD Mortality by cause for eight regions of the world: Global Burden of Disease (Pubitemid 27192468)
2. Murray CJ, Lopez AD Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997 ; 349 (9064). 1498-1504. (Pubitemid 27216360)
3. Woo J., Leung SS, Ho SC, Lam TH, Janus ED Dietary intake and practice in the Hong Kong Chinese population. J Epidemiol Community Health. 1998 ; 52 (10). 631-637. (Pubitemid 28464056)
4. Zhang X., Patel A., Horibe H., et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003 ; 32 (4). 563-572. (Pubitemid 37039010)
5. Ritchie GM, Keech AC, ASPAC Collaborative Group. Asia-Pacific collaboration on coronary heart disease risk factor intervention: study design and methods. Heart Lung Circ. 2001 ; 10 (1). 24-29. (Pubitemid 32519714)
6. Janus ED, Postigilone A., Singh RB, Lewis B. The modernization of Asia. Implications for coronary heart disease. Council on Arteriosclerosis of the International Society and Federation of Cardiology. Circulation. 1996 ; 94 (11). 2671-2673.
7. Government of Hong Kong Special Administrative Region, Department of Health. Healthy Hong Kong. Public Health Information and Statistics of Hong Kong. http://www.healthyhk.gov.hk/. Accessed May 26, 2007.
8. Lee VWY, Chan WK, Lam NLC, et al. Cost of acute myocardial infarction in Hong Kong. Dis Manag Health Outcome. 2005 ; 13 (4). 281-285. (Pubitemid 41127285)
9. Colquhoun D. Issues in managing hyperlipidaemia. Aust Fam Physician. 2000 ; 19 (3). 215-219.
10. Lipsy RJ Effective management of patients with dyslipidaemia. Am J Manag Care. 2003 ; 9 (suppl 2). S39 - S58.
11. Jacobson TA Clinical context: current concepts of coronary heart disease management. Am J Med. 2001 ; 110 (suppl6A). 3S - 11S. (Pubitemid 32322694)
12. Borenstein JE, Graber G., Saltiel E., et al. Physician-pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherpy. 2003 ; 23 (2). 209-216. (Pubitemid 36204018)
13. Choe HM, Mitrovich S., Dubay D., Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized trial. Am J Manag Care. 2005 ; 11 (4). 253-260. (Pubitemid 40569748)
14. Lee VWY, Leung PY Glycemic control and medication compliance in diabetic patients in a pharmacist-managed clinic in Hong Kong. Am J Health-Syst Pharm. 2003 ; 60 (24). 2593-2596.
15. Smith MD, Mcghan WF, Lauger G. Pharmacist counselling and outcomes of smoking cessation. Am Pharm. 1995 ; 8: 20-32.
16. Garabedian-Ruffalo SM, Gray DR, Sax MJ, Ruffalo RL Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm. 1985 ; 42 (2). 304-308. (Pubitemid 15162740)
17. Wong SW, Gray ES Clinical pharmacy services in oncology clinics. J Oncol Pharm Pract. 1999 ; 5 (1). 49-54.
18. Olson KL, Rasmussen J., Sandhoff BG, et al. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med. 2005 ; 165 (1). 49-54. (Pubitemid 40096081)
19. Bogden PE, Koontz LM, Williamson P., Abbott RD The physician and pharmacist team: an effective approach to cholesterol reduction. J Gen Int Med. 1997 ; 12 (3). 158-164. (Pubitemid 27180568)
20. Lee SSC, Chow MSS. Benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidaemia in Hong Kong. J Clin Pharmacol. 2004 ; 44: 632-669.
21. Petrie A., Sabin C. Sample size calculations. In: Petrie A, Sabin C, eds. Medical Statistics at a Glance. Oxford, UK: Blackwell Science; 2000: 84-86.
22. Wu JY, Leung WY, Chang S., et al. Effectiveness of telephone counseling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomized controlled trial. Br Med J. 2006 ; 333 (7567). 522-527.
23. Kiortsis DN, Giral P., Bruckert E., et al. Factors associated with low compliance with lipid-lowering drugs in hyperlipidaemic patients. J Clin Pharm Ther. 2000 ; 25 (6). 445-451. (Pubitemid 32055602)
24. Munroe WP, Kunz K., Dalmady-Israel C., Potter L., Schonfeld WH Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther. 1997 ; 19 (1). 113-123. (Pubitemid 27186443)
25. Brewer HB Increasing HDL cholesterol levels. N Engl J Med. 2004 ; 350 (15). 1491-1494.
26. Olson KL, Rasmussen J., Sandhoff BG, Merenich JA Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med. 2005 ; 165 (1). 49-54. (Pubitemid 40096081)
27. Bogden PE, Koontz LM, Williamson P., Abbott RD The physician and pharmacist team: an effective approach to cholesterol reduction. J Gen Int Med. 1997 ; 12 (3). 158-164. (Pubitemid 27180568)
28. Bozovich M., Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education program low-density lipoprotein goals. Pharmacotherapy. 2000 ; 20 (11). 1375-1383.
29. O'Donnell DC, Chen NTW, Piziak V. Goal attainment and maintenance of serum cholesterol level in a pharmacist-coordinated lipid clinic. Am J Health Syst Pharm. 2001 ; 58 (4). 325-330. (Pubitemid 32155290)
30. Konzem SL, Gray DR, Kashyap ML Effect of pharmaceutical care on optimum colestipol treatment in elderly hypercholesterolaemic veterans. Pharmacotherapy. 1997 ; 17 (3). 576-583. (Pubitemid 27227564)
31. Pearson TA, Laurora I., Chu A., et al. The Lipid Treatment Assessment Project (L-TAP). A multicentre survey to evaluate the percentages of dyslipidaemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Int Med. 2000 ; 160: 459-167.
32. LaRosa JH, LaRosa JC Enhancing drug compliance in lipid-lowering treatment. ArchFamily Med. 2000 ; 9 (10). 1169-1175.
33. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidaemic drugs: do rates reported in clinical trials reflect rates in primary care settings ? N Engl J Med. 1995 ; 332: 1125-1131.
34. Chui W., Chan P., Cheung P. The level of drug non-compliance of chronic patients in Hong Kong. Hong Kong Pharm J. 2002 ; 11 (3). 90-91.
35. Wei L., Wang J. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002 ; 88 (3). 229-233. (Pubitemid 34913500)
36. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004 ; 110 (2). 227-239. (Pubitemid 38924592)
37. Ito MK Role of the pharmacist in establishing lipid intervention programs. Pharmacotherapy. 2003 ; 23 (9). 41S - 47S. (Pubitemid 37158773)